Amylyx Pharmaceuticals Faces Class Action Lawsuits Over Misleading Statements

Investors allege the company overstated the commercial prospects of its ALS treatment, RELYVRIO, leading to significant losses.

• Multiple law firms have filed class action lawsuits against Amylyx Pharmaceuticals, Inc., alleging the company made false and misleading statements about its ALS treatment, RELYVRIO.
• Investors claim they were misled about RELYVRIO's commercial prospects, prescription rates, and patient discontinuation rates.
• The lawsuits allege Amylyx attempted to hide negative trends by blocking analysts from viewing prescription data.
• Investors have until April 9, 2024, to file lead plaintiff applications in the securities class action lawsuit.
• Amylyx's stock price fell significantly following the disclosure of its Q3 2023 financial results and the revelation of increased patient discontinuations.

3 Articles

Benzinga Benzinga Benzinga